reason report
bottom line morn report in-lin revenu
small ep beat versu consensu increas ep
guidanc reflect strong howev manag
commentari guidanc somewhat cautiou
left revenu guidanc unchang guidanc includ
expect hcv revenu declin sequenti
forecast global humira growth first
single-digit growth rate sinc humira perform
undermin lack posit price us share
price loss biosimilar europ begin base
quarterli result manag comment guidanc
lower revenu forecast ep forecast
price target reduc reiter
market perform rate abbvi stock could becom attract
recent launch gather momentum new launch
get underway time comfort remain
sidelin even upsid adjust target
guidanc increas margin perform share repurchas
strength oper allow manag increas ep
guidanc year boost expect full-year gross
oper margin oper strength appear less durabl
context guidanc forthcom competit factor
exampl humira consensu match driven ex-u result
geograph strength unlik continu biosimilar enter
market start similarli total revenu would
miss consensu strong hcv beat manag
guidanc lower patient volum also concern investor
product categori growth profil
remain industri leader even benefit tax reform
compani stock repurchas remov near-term
expect larg captur compani ev
long-term durabl growth remain question
previous cover highlight
confer call recap note link
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
compani inform leerink partner llc research
revenu mm dilut ep includ option expens present
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target per share stock rate market perform
transit corpor ownership success independ
biopharmaceut compani mani best featur biotech pharma
resourc expertis infrastructur diversif larg pharma competitor
specialti product profil growth rate matur biotechnolog compani remain
highli depend singl franchis humira sale total sale
suggest us valuat still discount compar diversifi peer
us biosimilar settlement competitor appear reassur investor
fear biosimilar entri exagger invalid expect oncolog product
imbruvica venclexta becom signific product gener
revenu compani next-gener hcv regimen boost
market share consider declin market look compani array
promis late-stag clinic medicin inflamm metabol diseas struggl
expand oncolog franchis beyond imbruvica venclexta current pipelin product
contribut revenu growth unlik materi dilut massiv
headwind face biosimilar enter market compet humira
ex-u humira hcv continu support top line total product revenu
line consensu miss estim prior
quarter main contributor top-lin result ex-u humira sale hcv
tenuou futur growth opportun due biosimilar entri shrink patient market
hcv global humira sale sequenti line
consensu forecast us humira revenu
slightli consensu ex-u humira revenu beat consensu
estim us imbruvica sale grew sequenti
consensu forecast abbvi row profit share
imbruvica grew qoq consensu hcv revenu
quarter viekira mavyret biggest outlier us hcv revenu
increas sequenti came consensu estim
expect row hcv revenu decreas sequenti came
consensu estim expect product sale mostli
strong quarter signific consensu beat kaletra
lower expens contribut ep beat oper expens
consensu expect estim non-gaap expens
less consensu estim non-gaap sg
expens line consensu lower estim
result oper margin improv better
consensu expect abbvi tax rate in-lin expect
guidanc result report non-gaap ep consensu
estim averag dilut share outstand reduc
prior quarter purchas roughli share recent dutch
tender mean share reduct occur gross stock option
dilut increment share count reduct certainli contribut significantli ep
growth back half year
full-year earn guidanc increas base oper result
quarter expect adjust ep rang increas
compar consensu updat estim abbvi
expect total revenu grow oper exclus addit fx tailwind
also increas oper margin guidanc flat compar
consensu updat estim also updat product level
revenu guidanc imbruvica mavyret key franchis humira compani
expect us imbruvica sale reach prior guidanc total hcv
sale exceed prior guidanc
scarc catalyst list includ minor event news flow
risankizumab upadacitinib complet two investig drug await regulatori
decis catalyst opportun fewer less impact back half
compani report full data orilissa elagolix uterin fibroid year file
label expans venclexta trial frontlin chronic lymphocyt leukemia cll
also anticip read trial compar efficaci safeti combin
regimen obinutuzumab venetoclax versu obinutuzumab chlorambucil believ
trial unlik import event given strategi posit imbruvica
domin frontlin agent cll also may releas data frontlin trial imbruvica
germin center b-cell subtyp diffus larg b-cell lymphoma dlbcl combin
rituximab-chemotherapi howev lack formal updat delay note dlbcl
trial lead us believ data could slip hand investor abbvi
stock alway expos risk neg headlin could includ updat
biosimilar develop launch europ major chang drug price
payment contract us could neg effect abbvi long term
outlook perceiv valu
model updat reduc us humira hcv estim pt follow result
guidanc revis revenu earn forecast better reflect compani
outlook decreas forecast humira
reflect loss price power us cautiou commentari
us growth ex-u biosimilar eros decreas revenu forecast mavyret
year captur expect manag competitor
number treat patient lessen go forward also reduc
forecast kaletra androgel given recent result total revenu forecast
decreas updat total revenu forecast
recent consensu consensu
continu forecast oper margin maintain
estim margin well forecast still assum signific
growth decreas estim pro-forma dilut ep
forecast increas remain recent
consensu pro-forma dilut ep consensu
net result adjust chang sector valuat multipl bring target
price previous
price target base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar larg biopharmaceut compani price sale multipl
larg cap peer compani stock discount cash flow dcf appli peer ep
revenu multipl use averag larg cap larg molecul therapeut compani mid-
term growth tail risk celg sni roch gsk averag
consensu ep multipl appli current ep estim
give valu use revenu multipl similar compani
consensu sale appli revenu estim give
valu lastli dcf valuat given wacc termin cash flow
growth rate begin humira biosimilar entri give present valu
averag three method current price target
risk view outlook valuat includ major chang price
outlook reimburs coverag label competit posit humira compani
main product risk includ commerci develop disappoint compani
follow-on program inflammatori diseas imbruvica venclexta expand
hematolog malign well competit posit compani next-
gener hcv therapi assum oper margin increas current level
toward fail reach sustain level would advers affect
forecast valuat also compani remain highli lever commit grow
dividend reduct forecast ebitda due neg busi trend would place
compani capit alloc strategi dividend growth risk opportun upsid
expect includ stronger-than-expect price volum share humira
emerg tangibl demand underappreci element compani early-to-
mid stage pipelin asset potenti label expans opportun late stage opportun
non-gaap cost good sold
interest expens
abbvi guidanc
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time event
leerink partner research compani report present clinicaltri gov
late stage pipelin program includ
late stage pipelin program exclud
bispecif mab i/o rova-t non-rova-t
million
leerink partner research compani file
million
good sold
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink target
method price base current larg cap hc stock mid-term growth tail risk
ep multipl appli ep rhhbi sni celg
leerink forma ep estim
method present valu base price sale multipl peer larg cap biopharma stock
averag price sale larg cap biopharma multipl
impli market cap mm estimate sale
anticip share count mm
method leerink probabl adjust dcf adjust net wacc termin
current leerink dcf marketed/l stage program
sourc leerink partner estim compani file factset
